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With more effective antiretroviral therapy (ART) provid-
ing opportunities for better long-term control of HIV-1
infection, there has been a shift in emphasis towards
reducing non-AIDS related morbidity and mortality. Con-
ditions affecting the cardiovascular system, central nerv-
ous system, kidneys and bone are particularly important
in maintaining long-term health in HIV-infected patients.
In the general population bone disease, such as oste-
oporosis and accompanying bone fractures, increases in
prevalence with age and causes significant morbidity, with
high costs associated with its management. Unlike other
long-term morbidities associated with HIV and ART, effec-
tive treatment options, such as bisphosphonates, can
improve bone mineralisation. Descriptions of abnormali-
ties in bone metabolism and mineralisation predate the
widespread introduction of combination ART and studies
have demonstrated high prevalence of low bone mineral-
ization in HIV-infected patients with consistent associa-
tions between the length of HIV infection and decreased
bone mineralization. However, both in vitro research and
evidence from clinical trials also show effects on bone
metabolism with exposure to both nucleoside reverse
transcriptase inhibitors and protease inhibitors with
emerging clinical data suggesting that most bone loss
occurs within the first year after initiation of therapy.
Despite these data, numerous questions remain to be
answered in relation to bone loss in HIV including the
natural history of bone loss in this clinical setting, when
maximum bone loss occurs, the nature of the underlying
pathology, the principal factors influencing bone loss,
what loss of bone mineralization is considered clinically
relevant, when and how often to monitor bone minerali-
zation and the appropriate thresholds for instituting ther-
apy to limit bone loss. These questions can only be
answered by large scale prospective studies from which
HIV-specific, evidence-based guidelines can be derived. In
order to appropriately manage long-term bone health in
HIV-infected patients, research strategies and sufficient
access to monitoring are needed to address the deficits in
our knowledge and enable appropriate monitoring of this
condition in the HIV setting so that this challenge to the
long-term health of HIV-infected patients is effectively
managed and the potential resulting morbidity limited.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):O32 doi:10.1186/1758-2652-11-S1-O32
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/O32
© 2008 Mallon; licensee BioMed Central Ltd. 
